{"id":"progesterone-lozenges","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Mood changes"}]},"_chembl":{"chemblId":"CHEMBL103","moleculeType":"Small molecule","molecularWeight":"314.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Progesterone is a naturally occurring steroid hormone that exerts its effects by binding to intracellular progesterone receptors (PR-A and PR-B), which function as ligand-activated transcription factors. The lozenge formulation allows for buccal/oral mucosal absorption, potentially providing more direct systemic delivery compared to other routes. This mechanism supports progesterone's role in maintaining pregnancy, regulating menstrual cycles, and modulating endometrial and breast tissue.","oneSentence":"Progesterone acts as a steroid hormone that binds to progesterone receptors to modulate reproductive and metabolic processes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:30:15.664Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Progesterone supplementation in pregnancy (likely indication given phase 3 status)"},{"name":"Menstrual cycle regulation or hormone replacement therapy (potential indication)"}]},"trialDetails":[{"nctId":"NCT05515354","phase":"PHASE4","title":"Smoking Cessation and Menstrual Cycle Phase","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-11-30","conditions":"Nicotine Dependence, Tobacco Smoking, Smoking Cessation","enrollment":1200},{"nctId":"NCT00029536","phase":"PHASE3","title":"Progesterone vs Placebo Therapy for Women With Epilepsy","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2000-10","conditions":"Epilepsy","enrollment":294}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Progesterone Lozenges","genericName":"Progesterone Lozenges","companyName":"Beth Israel Deaconess Medical Center","companyId":"beth-israel-deaconess-medical-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"Progesterone lozenges are being studied as a potential treatment for nicotine dependence and smoking cessation, with a clinical trial (NCT05515354) examining their effectiveness in combination with nicotine replacement therapy. As a small molecule progesterone receptor agonist, progesterone lozenges work by activating the progesterone receptor, a mechanism that has been identified through the ChEMBL database.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}